Innate Pharma's Shareholder Structure and Capital Flexibility

Innate Pharma, a clinical-stage biotechnology company specializing in immuno-oncology, has made significant strides in its pipeline and partnerships. As of December 31, 2024, the company's shareholder structure and capital position provide a solid foundation for its growth prospects. This article will delve into the number of shares and voting rights of Innate Pharma, as well as its capital structure and financial flexibility.



Innate Pharma's shareholder structure is well-diversified, with insiders owning 2.48% of the shares outstanding and institutions owning 1.78%. The float, representing the shares available for public trading, is 31.56 million, or approximately 39% of the shares outstanding. This distribution indicates a balanced ownership structure, with a significant portion of shares held by the public.



The company's capital structure is characterized by a strong liquidity position, with a current ratio of 2.92, and a relatively balanced debt-to-equity ratio of 1.23. Innate Pharma has a net cash position of €60.32 million or €0.75 per share, providing financial flexibility for future investments and growth. The company's cash position of €102.1 million as of June 30, 2024, is expected to last until the end of 2025, ensuring a runway for continued operations and pipeline development.

Innate Pharma's capital structure also supports its growth prospects through strategic partnerships with leading biopharmaceutical companies. These collaborations provide additional financial resources and expertise to help the company advance its pipeline and achieve its growth objectives.



Innate Pharma's pipeline includes several potential "first-in-class" candidates in clinical and preclinical stages, with a focus on immuno-oncology and innovative therapeutic antibodies. The company's multi-product partnerships with leading biopharmaceutical companies, such as Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and AstraZeneca, contribute to its financial stability and growth prospects.

In summary, Innate Pharma's shareholder structure and capital position provide a solid foundation for its growth prospects. The company's well-diversified shareholder base, strong liquidity, and balanced capital structure, combined with strategic partnerships, enable Innate Pharma to maintain financial flexibility and pursue its growth strategy. As the company continues to advance its pipeline and explore new opportunities, investors should keep a close eye on its progress and potential.